Literature DB >> 31723016

Mitochondrial Oxidative Phosphorylation Complex Regulates NLRP3 Inflammasome Activation and Predicts Patient Survival in Nasopharyngeal Carcinoma.

I-Che Chung1,2, Lih-Chyang Chen3, Ngan-Ming Tsang4,5, Wen-Yu Chuang6, Tzu-Chieh Liao7, Sheng-Ning Yuan2, Chun-Nan OuYang2, David M Ojcius8,9,10, Chih-Ching Wu11,12,13,14, Yu-Sun Chang15,2,14.   

Abstract

We previously reported that tumor inflammasomes play a key role in tumor control and act as favorable prognostic markers in nasopharyngeal carcinoma (NPC). Activated inflammasomes frequently form distinguishable specks and govern the cellular secretion of IL-1β. However, we know little about the biological and biochemical differences between cells with and without apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) speck formation. In this study, we used proteomic iTRAQ analysis to analyze the proteomes of NPC cells that differ in their ASC speck formation upon cisplatin treatment. We identified proteins that were differentially over-expressed in cells with specks, and found that they fell into two Gene ontology (GO) pathways: mitochondrial oxidative phosphorylation (OxPhos) and ubiquinone metabolism. We observed up-regulation of various components of the OxPhos machinery (including NDUFB3, NDUFB8 and ATP5B), and subsequently found that these changes lead to mitochondrial ROS (mtROS) production, which promotes the formation and activation of NLRP3 inflammasomes and subsequent pyroptosis. In NPC patients, better local recurrence-free survival was significantly associated with high-level expression of NDUFB8 (p = 0.037) and ATP5B (p = 0.029), as examined using immunohistochemistry. However, there were no significant associations between the expression of NDUFB8 and ATP5B with overall survival of NPC patients. Together, our results demonstrate that up-regulated mitochondrial OxPhos components are strongly associated with NLRP3 inflammasome activation in NPC. Our findings further suggest that high-level expression of OxPhos components could be markers for local recurrence and/or promising therapeutic targets in patients with NPC.
© 2020 Chung et al.

Entities:  

Keywords:  cancer biology; iTRAQ; inflammatory response; mitochondria function or biology; nasopharyngeal carcinoma; oxidative stress

Mesh:

Substances:

Year:  2019        PMID: 31723016      PMCID: PMC6944234          DOI: 10.1074/mcp.RA119.001808

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  51 in total

Review 1.  Gasdermins: Effectors of Pyroptosis.

Authors:  Stephen B Kovacs; Edward A Miao
Journal:  Trends Cell Biol       Date:  2017-06-12       Impact factor: 20.808

2.  Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line (NPC-BM1) derived from a bone marrow metastatic lesion.

Authors:  S K Liao; Y P Perng; Y C Shen; P J Chung; Y S Chang; C H Wang
Journal:  Cancer Genet Cytogenet       Date:  1998-05

Review 3.  Mitochondria are the powerhouses of immunity.

Authors:  Evanna L Mills; Beth Kelly; Luke A J O'Neill
Journal:  Nat Immunol       Date:  2017-04-18       Impact factor: 25.606

4.  ATP5b and β2-microglobulin are predictive markers for the prognosis of patients with gallbladder cancer.

Authors:  Jianning Sun; Zhu-Lin Yang; Xiongying Miao; Qiong Zou; Jinghe Li; Lufeng Liang; Guixiang Zeng; Senlin Chen
Journal:  J Mol Histol       Date:  2014-10-14       Impact factor: 2.611

Review 5.  Mitochondria in the regulation of innate and adaptive immunity.

Authors:  Samuel E Weinberg; Laura A Sena; Navdeep S Chandel
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

Review 6.  Inflammasome biology, molecular pathology and therapeutic implications.

Authors:  Fawaz Awad; Eman Assrawi; Camille Louvrier; Claire Jumeau; Sophie Georgin-Lavialle; Gilles Grateau; Serge Amselem; Irina Giurgea; Sonia-Athina Karabina
Journal:  Pharmacol Ther       Date:  2018-02-18       Impact factor: 12.310

Review 7.  Mitochondria as a centrally positioned hub in the innate immune response.

Authors:  Rajat Sandhir; Avishek Halder; Aditya Sunkaria
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-26       Impact factor: 5.187

Review 8.  Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.

Authors:  Henry Sze; Pierre Blanchard; Wai Tong Ng; Jean-Pierre Pignon; Anne W M Lee
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-20       Impact factor: 3.722

Review 9.  Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome.

Authors:  Tiffany Horng
Journal:  Trends Immunol       Date:  2014-03-16       Impact factor: 16.687

10.  Src-family kinase-Cbl axis negatively regulates NLRP3 inflammasome activation.

Authors:  I-Che Chung; Sheng-Ning Yuan; Chun-Nan OuYang; Hsin-Chung Lin; Kuo-Yang Huang; Yu-Jen Chen; An-Ko Chung; Ching-Liang Chu; David M Ojcius; Yu-Sun Chang; Lih-Chyang Chen
Journal:  Cell Death Dis       Date:  2018-10-31       Impact factor: 8.469

View more
  9 in total

1.  Analysis of Pyroptosis-Related Signature for Predicting Prognosis and Tumor Immune Microenvironment in Pancreatic Cancer.

Authors:  Lincheng Li; Zhaoda Deng; Zhaohui Xiao; Wenbo Zou; Rong Liu
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

2.  Dexmedetomidine Enhances Autophagy via α2-AR/AMPK/mTOR Pathway to Inhibit the Activation of NLRP3 Inflammasome and Subsequently Alleviates Lipopolysaccharide-Induced Acute Kidney Injury.

Authors:  Tianyuan Yang; Xiujing Feng; Yuan Zhao; Haiyang Zhang; Hailin Cui; Mian Wei; Haotian Yang; Honggang Fan
Journal:  Front Pharmacol       Date:  2020-06-24       Impact factor: 5.810

3.  MitoQ Is Able to Modulate Apoptosis and Inflammation.

Authors:  Elisa Piscianz; Alessandra Tesser; Erika Rimondi; Elisabetta Melloni; Claudio Celeghini; Annalisa Marcuzzi
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

4.  Clinical Relevance and Tumor Growth Suppression of Mitochondrial ROS Regulators along NADH:Ubiquinone Oxidoreductase Subunit B3 in Thyroid Cancer.

Authors:  Jiao Zhu; Xiaobo Zheng; Dan Lu; Yun Zheng; Jun Liu
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

5.  NLRP3 inflammasome promoted the malignant progression of prostate cancer via the activation of caspase-1.

Authors:  Zheng Xu; Hao Wang; Zhiqiang Qin; Feng Zhao; Liuhua Zhou; Luwei Xu; Ruipeng Jia
Journal:  Cell Death Discov       Date:  2021-12-20

6.  Prototheca spp. induce an inflammatory response via mtROS-mediated activation of NF-κB and NLRP3 inflammasome pathways in bovine mammary epithelial cell cultures.

Authors:  Wenpeng Zhao; Fumeng He; Herman W Barkema; Siyu Xu; Jian Gao; Gang Liu; Zhaoju Deng; Muhammad Shahid; Yuxiang Shi; John P Kastelic; Bo Han
Journal:  Vet Res       Date:  2021-12-11       Impact factor: 3.683

Review 7.  Evidence for the Role of Mitochondrial DNA Release in the Inflammatory Response in Neurological Disorders.

Authors:  Gonzalo E Moya; Phillip D Rivera; Kristin E Dittenhafer-Reed
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

8.  A genome-wide screen uncovers multiple roles for mitochondrial nucleoside diphosphate kinase D in inflammasome activation.

Authors:  Orna Ernst; Jing Sun; Bin Lin; Balaji Banoth; Michael G Dorrington; Jonathan Liang; Benjamin Schwarz; Kaitlin A Stromberg; Samuel Katz; Sharat J Vayttaden; Clinton J Bradfield; Nadia Slepushkina; Christopher M Rice; Eugen Buehler; Jaspal S Khillan; Daniel W McVicar; Catharine M Bosio; Clare E Bryant; Fayyaz S Sutterwala; Scott E Martin; Madhu Lal-Nag; Iain D C Fraser
Journal:  Sci Signal       Date:  2021-08-03       Impact factor: 9.517

9.  Detection of In Vivo Inflammasome Activation for Predicting Sepsis Mortality.

Authors:  Jing Cui; Stephanie Oehrl; Fareed Ahmad; Thorsten Brenner; Florian Uhle; Christian Nusshag; Christoph Rupp; Felix Funck; Stefan Meisel; Markus A Weigand; Christian Morath; Knut Schäkel
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.